Silverback Therapeutics (NASDAQ:SBTX) Shares Down 3% – Should You Sell?

Silverback Therapeutics, Inc. (NASDAQ:SBTX)’s stock price fell 3% during trading on Thursday . The stock traded as low as $5.2150 and last traded at $5.23. 874,545 shares changed hands during mid-day trading, an increase of 159% from the average session volume of 337,931 shares. The stock had previously closed at $5.39.

Silverback Therapeutics Stock Down 3.0%

The company has a fifty day simple moving average of $6.31 and a 200-day simple moving average of $7.79. The firm has a market cap of $188.58 million, a P/E ratio of -2.16 and a beta of 0.60.

About Silverback Therapeutics

Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.

Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.